RE:RE:EY sees bolt-ons in the single to double digit billions now AstraZeneca on the hunt for new acquisitions _ September 11, 2022
On 23 August, at a Reuters Newsmakers online forum, AstraZenea's CEO Pascal Soriot announced his interest in increasing AstraZeneca’s portfolio of bolt-on acquisitions leading up to 2025. Soriot said AstraZeneca is particularly interested in oncology, cardiovascular disease, and rare diseases, and taking part in more ‘small to mid-size’ bolt-on acquisitions in the upcoming years.
In the past four years AstraZeneca has taken part in five oncology and respiratory disease deals, respectively. These have been major steps in the company’s plan to expand its portfolio.
Soriot highlighted key considerations that contribute to the decision to integrate a company into the fold. AstraZeneca is interested in incorporating a new pipeline to its portfolio, “provided it really fits our strategy, we can add value, we think we can integrate the product, the team and the company that we acquire, they fit culturally within our company and geographically we can execute on the integration. But essentially [this is] driven by our strategy and focusing on what we want to achieve as a company,” explained Soriot.